Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine
| Status: | Archived |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2010 |
Phase 1/2a Trial to Assess the Safety, Immunogenicity and Efficacy of Genetically-attenuated Plasmodium Falciparum Parasites p52-/p36- (GAP) Vaccine, Administered by Bite of Infected Anopheles Mosquito to Malaria-naïve Adults Living in the United States.
The purpose of this study is to assess safety and tolerability of escalating doses of a
genetically attenuated parasite malaria vaccine (p52-/p36- GAP vaccine) in healthy
malaria-naive adults. The study will also assess preliminary efficacy of p52-/p36- GAP
vaccine following primary experimental challenge with P. falciparum sporozoites. Lastly,
the study will assess immunogenicity of p52-/p36- GAP in malaria-naïve healthy adults and
preliminary efficacy of p52-/p36- GAP vaccine following primary experimental re-challenge
with P. falciparum sporozoites.
We found this trial at
1
site
Click here to add this to my saved trials
